Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
More patients than ever stand to benefit from a promising new type of cancer treatment, after scientists compiled a library of molecules that can prime patients' immune systems to fight a range of cancers including leukaemia, myeloma, lung cancer and skin cancer.
The UK and Dutch researchers developed a rapid DNA sequencing technology that newly identified 21 different molecules, called T cell receptors (TCRs), that can recognise markers found in cells from 11 different subsets of cancer.
White blood cells known as killer T cells are the assassins of the immune system and it is their job to seek out and destroy infected cells. They can also potentially kill cancer cells but often fail to do so, partly because our immune system is programmed not to attack our own bodies. Since cancer cells are formerly healthy cells that are growing out of control, T cells normally do not recognise them as a threat.
Treatment called 'immunotherapy' works by taking a sample of T cells from the blood of a cancer patient and inserting TCR genes that recognise specific markers, or 'antigens', carried by cancer cells. When these modified T cells are reintroduced into to the patient, the T cells can hunt down and kill cancer cells, while sparing healthy cells. This approach has already been tested in patients with a variety of cancers, including blood cancers and skin cancers, with very promising results.
Unfortunately, antigens found on patients' cancer cells vary considerably and if the engineered T cells are not matched exactly to recognise each cancer subset, then the immunotherapy will not be effective.
Dr Gavin Bendle, now based at the University of Birmingham, was funded by Leukaemia & Lymphoma Research to carry out the research with Dr Carsten Linnemann and Prof Ton Schumacher at The Netherlands Cancer Institute. He said, "To be able to treat large numbers of patients with different types of cancer, large collections of TCRs specific to each cancer subset are needed. The DNA scanning technology that we have developed enabled us to rapidly assemble a library of TCRs that have the potential to be used to treat many cancer types and subtypes."
The research is published online in the journal Nature Medicine.
Professor Chris Bunce, Research Director of Leukaemia & Lymphoma Research, said, "For the past decade, immunotherapy has been seen by some as the holy grail of targeted cancer treatment, especially for those patients who cannot be cured with standard chemotherapy drugs. It has had very promising results in patients with a variety of cancers but it does not work in all cases and can be laborious to produce. This study is a highly significant step forward in individualising immunotherapy in a rapid way, making it a potential cure for more cancer patients than ever before."
Dr Bendle, now based at the School of Cancer Sciences at the University of Birmingham, is currently running a five-year study, also funded by Leukaemia & Lymphoma Research, to refine which TCRs from the library are best suited to treating patients with myeloma, an as-yet incurable type of blood cancer. These TCRs will then be tested in clinical trials for myeloma patients.
Authors: Carsten Linnemann, Bianca Heemskerk, Pia Kvistborg, Roelof J C Kluin, Dmitriy A Bolotin, Xiaojing Chen, Kaspar Bresser, Marja Nieuwland, Remko Schotte, Samira Michels, Raquel Gomez-Eerland, Lorenz Jahn, Pleun Hombrink, Nicolas Legrand, Chengyi Jenny Shu, Ilgar Z Mamedov, Arno Velds, Christian U Blank, John B A G Haanen, Maria A Turchaninova, Ron M Kerkhoven, Hergen Spits, Sine Reker Hadrup, Mirjam H M Heemskerk, Thomas Blankenstein, Dmitriy M Chudakov, Gavin M Bendle & Ton N M Schumacher
Nature Medicine (2013) doi:10.1038/nm.3359
Leukaemia & Lymphoma Research
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Cancer / Oncology category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Leukaemia & Lymphoma Research. "DNA scanning technology leads to new library of cancer targets." Medical News Today. MediLexicon, Intl., 16 Oct. 2013. Web.
5 Dec. 2013. <http://www.medicalnewstoday.com/releases/267459>
Leukaemia & Lymphoma Research. (2013, October 16). "DNA scanning technology leads to new library of cancer targets." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/267459.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.